nivolumab,ipilimumab
bms
['crcsm', 'ipilimumab', 'nivo', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nivolumab', 'niche-2']
impressive results from niche-2 trial may open a way to a watch and wait approach for patients with stage iii dmmr #crc: 95% major pathologic responses (67% pcr) with neoadjuvant immunotherapy (io) ipilimumab + nivolumab #esmo22 #crcsm 
We FIGHT to cure #colorectalcancer and serve as #RelentlessChampions of hope for all affected by this disease! ????